RAINER STORB, M.D.; E. DONNALL THOMAS, M.D.; C. DEAN BUCKNER, M.D.; REGINALD A. CLIFT, F.I.M.L.S.; H. JOACHIM DEEG, M.D.; ALEXANDER FEFER, M.D.; BRIAN W. GOODELL, M.D.; GEORGE E. SALE, M.D.; JEAN E. SANDERS, M.D.; JACK SINGER, M.D.; PATRICIA STEWART, M.D.; PAUL L. WEIDEN, M.D.
Thirty patients with severe aplastic anemia had no transfusions of blood products until just before marrow transplantation from HLA-identical family members. They were conditioned for grafting with cyclophosphamide, 50 mg/kg body weight on each of 4 successive days. All 30 had prompt initial marrow engraftment, which was sustained in 27. Twenty-five of the 30 are alive between 9 to 84 (median, 19.5) months. The actuarial projection of survival for 2 to 6 years is 75%. Twenty of the 25 surviving patients have no problems. Five have chronic graft-versus-host disease, resolving in two and active in three. Five patients died with infection or hemorrhage, four of whom had graft-versus-host disease. These data show that early transplantation should be carried out before transfusions are given for any patient with severe aplastic anemia who has an HLA-identical family member. If sensitization to minor transplantation antigens contained in blood products is avoided, the incidence of marrow-graft rejection will decrease, and survival will improve.
STORB R, THOMAS ED, BUCKNER CD, et al. Marrow Transplantation in Thirty "Untransfused" Patients with Severe Aplastic Anemia. Ann Intern Med. 1980;92:30–36. doi: https://doi.org/10.7326/0003-4819-92-1-30
Download citation file:
Published: Ann Intern Med. 1980;92(1):30-36.
Hematology/Oncology, Red Cell Disorders.
Results provided by:
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use